에 대한 최신 뉴스 Mustang Bio (NASDAQ:MBIO) 주식

Mustang Bio

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Equities

News

Markets

General

DKNG

MBIO

PLTR

TSLA

월요일, 미국 주요 지수는 상승세를 보였다. 다우존스 산업평균지수는 0.5% 가까이 오른 38,778.10에 마감했고, S&amp;P 500 지수는 0.8% 가까이 오른 5,473.23에, 나스닥 지수는 0.95% 상승한 17,857.02에 마감했다. 이들은 하루 동안 소매 거래자와 투자자들의 주목을 받은 인기 종목들이다:

월요일 주목받은 주식 5종목: 팔란티어, 머스탱 바이오, 드래프트킹스, 마이크론, 테슬라

Mustang Bio Inc

T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) has outperformed the market over the past 10 years by 10.95% on an annualized basis producing an average annual return of 22.26%. Currently, T-Mobile US has a market capitalization of $263.42 billion. 
Buying $1000 In TMUS: If an investor had bought $1000 of TMUS stock 10 years ago, it would be worth $7,576.26 today based on a price of $230.15 for TMUS at the time of writing.
<h3>T-Mobile US's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738367108_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

TMUS

Here's How Much You Would Have Made Owning T-Mobile US Stock In The Last 10 Years

Moodys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) has outperformed the market over the past 15 years by 9.35% on an annualized basis producing an average annual return of 21.63%. Currently, Moodys has a market capitalization of $90.51 billion. 
Buying $100 In MCO: If an investor had bought $100 of MCO stock 15 years ago, it would be worth $1,826.77 today based on a price of $499.44 for MCO at the time of writing.
<h3>Moodys's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738366209_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Moodys 15 Years Ago Would Be Worth This Much Today

Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) has outperformed the market over the past 10 years by 3.45% on an annualized basis producing an average annual return of 14.76%. Currently, Morgan Stanley has a market capitalization of $223.31 billion. 
Buying $100 In MS: If an investor had bought $100 of MS stock 10 years ago, it would be worth $398.13 today based on a price of $138.96 for MS at the time of writing.
<h3>Morgan Stanley's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738365312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Morgan Stanley 10 Years Ago Would Be Worth Today

Howmet Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) has outperformed the market over the past 5 years by 27.37% on an annualized basis producing an average annual return of 40.21%. Currently, Howmet Aerospace has a market capitalization of $51.19 billion. 
Buying $100 In HWM: If an investor had bought $100 of HWM stock 5 years ago, it would be worth $549.37 today based on a price of $126.01 for HWM at the time of writing.
<h3>Howmet Aerospace's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738364409_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) has outperformed the market over the past 10 years by 11.42% on an annualized basis producing an average annual return of 22.73%. Currently, Veeva Systems has a market capitalization of $37.87 billion. 
Buying $1000 In VEEV: If an investor had bought $1000 of VEEV stock 10 years ago, it would be worth $7,775.33 today based on a price of $233.26 for VEEV at the time of writing.
<h3>Veeva Systems's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738363509_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VEEV

Here's How Much $1000 Invested In Veeva Systems 10 Years Ago Would Be Worth Today

Ares Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) has outperformed the market over the past 10 years by 15.37% on an annualized basis producing an average annual return of 26.68%. Currently, Ares Management has a market capitalization of $39.86 billion. 
Buying $1000 In ARES: If an investor had bought $1000 of ARES stock 10 years ago, it would be worth $10,493.38 today based on a price of $197.42 for ARES at the time of writing.
<h3>Ares Management's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738362616_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARES

Here's How Much $1000 Invested In Ares Management 10 Years Ago Would Be Worth Today

<h2 class="wp-block-heading">Introduction</h2>
Throughout the last two years, the stock market has experienced above-average total returns — with the Nasdaq-100 delivering investors a 54.8% return in 2023 and a 25.5% return in 2024. Compare this to the 11.8% average annual return the Nasdaq-100 has delivered since its inception in 1985.
As we enter 2025, not only have we experienced the best back-to-back years in the stock market since 1997 &amp; 1998 — we're objectively over-valued, historically speaking. At time of writing, the P/E ratio of the Nasdaq-100 sits at 31.3X — materially higher than the 10-year median of 25.3X. With that being said, I'd argue valuations are not what end secular bull markets. During secular bull markets, valuations can always go higher — just like during secular bear markets valuations can always go lower as fear and greed move markets from one side to the other much like a pendulum.
Under the Trump Administration, I'd argue the Federal Reserve will continue to cut interest rates. When you pair these rate cuts with a healthy economy you get the below chart — history tells us we could experience double-digit gains.
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="713" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/31203447/Screenshot-2025-01-31-143423-1024x713.png" alt="BofA Global Research" class="wp-image-5314" style="width:920px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/31203447/Screenshot-2025-01-31-143423-1024x713.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/31203447/Screenshot-2025-01-31-143423-300x209.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/31203447/Screenshot-2025-01-31-143423-768x534.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/01/31203447/Screenshot-2025-01-31-143423.png 1184w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
With that being said, I'm a firm believer that we're not going to avoid market volatility in 2025 to the degree we did throughout both 2023 and 2024. During both of those years the largest decline the index experienced was -10%, one during July 2023 and another during August 2024. Compare those -10% declines to the average -12-15% annual decline we've historically experienced during bull markets, according to JPMorgan Chase.
Pair this expected heightened volatility with a historically volatile Trump Administration and you have yourself a recipe for some unpredictable returns in the Nasdaq-100 throughout 2025.
Introducing the <a href="https://www.benzinga.com/quote/QQQI">NEOS Nasdaq-100 High Income ETF (QQQI)</a> — how I'm preparing for volatility in 2025 without leaving too much potential upside on the table in case I'm wrong.
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h2 class="wp-block-heading">What is QQQI?</h2>
The <a href="https://www.benzinga.com/quote/qqqi">NEOS Nasdaq-100 High Income ETF (QQQI)</a> is a covered call ETF that seeks to distribute high monthly income to their investors. They generate this high monthly income by investing into all of the underlying constituents of the Nasdaq-100 and implementing a data-driven call option strategy.
A few things set this fund apart from their peers like JEPQ and QYLD.
Unlike JEPQ, the NEOS Nasdaq-100 High Income ETF (QQQI) holds all 100 constituents of the <a href="https://www.benzinga.com/quote/qqq">Nasdaq-100 index</a>. There's no "cherry picking" of names their fund managers think might be under-valued. Instead, QQQI investors know exactly what they're signing up for.
Additionally, QQQI's data-driven call option strategy utilizes Nasdaq-100 Index Options which is important for two reasons:
<ol>
<li>Index options are classified as <a href="https://www.investopedia.com/terms/s/section-1256-contract.asp#:~:text=A%20Section%201256%20contract%20specifies,term%20capital%20gains%20or%20losses.">Section 1256 contracts</a> by the IRS. This means no matter the holding period, all income generated from these contracts are taxed at 60% long-term capital gains and 40% short-term capital gains. </li>
<li>Additionally, the fund portfolio managers aim to harvest losses within the portfolio to either offset gains in the option contracts or equity positions &#8211; which can allow fund distributions to be classified as a &#8220;Return of Capital.&#8221;
<ul>
<li><a href="https://www.investopedia.com/terms/r/returnofcapital.asp">Return of Capital</a> distributions are not taxable in the year they&#8217;re received, instead investors would pay long-term capital gains on their distributions if / when they ever decide to sell their shares. This is especially important for investors looking to lower their annual tax burden as you&#8217;re essentially converting short-term income distribution payments into long-term capital gains treatment in the event of a future sale of the ETF.</li>
</ul>
</li>
</ol>
Compare all of this to <a href="https://www.benzinga.com/quote/JEPQ">JEPQ's</a> equity-linked notes (ELNs) — a terrible income-generation strategy that forces investors to pay ordinary income tax on their distributions.
Unlike <a href="https://www.benzinga.com/quote/qyld">QYLD</a>, the NEOS Nasdaq-100 High Income ETF (QQQI) doesn't sell call options against the entire value of the fund's portfolio — <a href="https://youtu.be/8xykeGA5eJU?si=D_QUAollXVy_diPR">but instead against only 75-90%</a>. This means the other 10-25% of the portfolio can move freely up and down with the markets and is not "capped" by the strike price of the call option. As a result, gains are not limited to only the premiums received from the sold calls — which is the unfortunate reality for QYLD investors.
The result is the price of QQQI moves much more freely alongside QQQ when compared to QYLD.
For example, during the weeks throughout April 22 and July 18, 2024 shares of QQQ appreciated by +18.5%. During the same period of time, shares of QYLD appreciated only 4.4%, whereas shares of QQQI appreciated +9.8%. That +5.4% outperformance from QQQI was catalyzed by their fund managers strategically writing call options against only a portion of their fund's notional value instead of the entirety of its value like QYLD.
Not to mention, that +9.8% appreciation in share price doesn&#8217;t include the $2.44 per share of income paid to QQQI investors during that three month stretch (~5.0% yield). 
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h2 class="wp-block-heading">How Has QQQI Performed During This Bull Market? </h2>
QQQI was introduced to investors on January 30th, 2024. Shares of the fund began trading at $50 per share. Now that we officially have an entire year of performance to review, let's see how QQQI did.
The 1-year <a href="https://www.morningstar.com/etfs/xnas/qqqi/performance">total return of QQQI was 22.7%</a>.
Throughout those 12-months, QQQI paid their investors $7.33 per share in total distributions. Assuming you purchase one share of QQQI for $50 on January 30th, 2024 — that's a 14.7% annual distribution yield.
Throughout the last 12-months, the share price of QQQI appreciated by +8.3% — when combined with their annual distribution yield brings us to having captured 95.8% of the <a href="https://www.morningstar.com/etfs/xnas/qqq/performance">Nasdaq-100's total return</a> during the same period of time.
I'd argue QQQI has performed quite well during this bull market, capturing nearly 96% of their benchmark index's total returns. Remember, the objective of this fund is not to out-perform its underlying benchmark index, but instead generate high tax-efficient monthly income for their investors.
And at a 14.7% annual distribution yield, I'd argue they accomplished that objective during their first year of trading.
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h2 class="wp-block-heading">How Will QQQI Perform During Volatility? </h2>
Now let's answer the million dollar question — how will QQQI and other covered call ETFs perform during times of volatility?
Well, let's first define what is going to cause the volatility.
For JEPQ, their fund managers have the autonomy to buy and sell specific names inside of their ETF to potentially offset market volatility. With that being said, JEPQ began trading on the open markets May 4, 2022 at $50.10 per share. On October 13, 2022 shares of JEPQ fell as low as $39.61 — a dramatic -20.8% decline in share price. With that being said, throughout that period of time they paid their investors $2.06 per share in cumulative distributions — a 4.1% yield against their open price of $50.10 in May.
From May 4, 2022 to October 13, 2022 JEPQ investors were looking at a -20.8% decline in price per share, which was more than QQQ's -20.3% decline in price per share during the same period of time.
Historically speaking, JEPQ's proprietary stock picking strategy does not offset price volatility during bear markets. The only way JEPQ was able to offset volatility was by generating monthly income for their investors.
Considering QYLD's fund managers do not implement a proprietary stock picking strategy and instead just hold the constituents of the underlying index, theoretically speaking the only way QYLD could outperform QQQ during a bear market is by paying their investors a monthly yield as the two funds' holdings are exactly the same.
Assuming this is true, then QQQI theoretically should also experience the same price decline as QQQ during a bear market — with the only outperformance coming from their monthly income. And considering QQQI pays their investors a 14.7% annual distribution yield (<a href="https://x.com/NEOSInvestments/status/1882760470291214803">link</a>) compared to QYLD's 12.7% (<a href="https://www.globalxetfs.com/funds/qyld/">link</a>), that's a 2% difference in the positive direction for QQQI.
Now when you pair that 2% theoretical difference with the outperformance QQQI has already demonstrated during rising markets (5.4% throughout April-July 2024), QQQI has the opportunity to 1) materially outperform its competitors while 2) offsetting a potential decline in price with its tax-efficient high monthly income if we experience volatility in 2025.
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h2 class="wp-block-heading">Summary</h2>
I cannot predict what the Nasdaq-100 will do in 2025. There is clear evidence of the index being historically overvalued, but I'm also a firm believer in the ideology that valuations can always be driven higher by greed. Considering the lack of volatility the index experienced in 2023 and 2024, I have reason to believe we'll experience multiple double-digit pullbacks in the Nasdaq-100 throughout the year.
Assuming that is true, I believe holding shares of QQQI in my portfolio will be the best way to play this looming volatility as the income generated by the shares will offset any price declines experienced by the Nasdaq-100 while their data-driven covered call strategy on only a portion of the fund's notional value will allow for price appreciation in rising markets as well.
Offsetting share price decline with tax-efficient monthly income while participating in rising markets is a recipe for success in 2025.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Disclaimer: This is not financial advice or recommendation for any investment. The content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. I/we have a beneficial long position in the shares of BTCI, SPYI, QQQI, and IWMI either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor

Market Summary

Tech

ETFs

QQQI: How I'm Preparing for Volatility in 2025

Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) has outperformed the market over the past 15 years by 19.59% on an annualized basis producing an average annual return of 31.87%. Currently, Fortinet has a market capitalization of $77.18 billion. 
Buying $100 In FTNT: If an investor had bought $100 of FTNT stock 15 years ago, it would be worth $6,429.57 today based on a price of $100.70 for FTNT at the time of writing.
<h3>Fortinet's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738361716_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FTNT

$100 Invested In Fortinet 15 Years Ago Would Be Worth This Much Today

Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) on Thursday reported better-than-expected fourth-quarter results but lowered its forward guidance for the next quarter. Analysts <a href="https://www.benzinga.com/news/earnings/25/01/43354712/intel-stock-climbs-on-better-than-expected-q4-report-details">weighed in on the report.&nbsp;</a>
Expert Ideas: Cantor Fitzgerald analyst C.J. Muse highlighted Intel's better-than-feared fourth quarter driven by the Intel Products side with Foundry results coming in as expected.&nbsp;
The analyst also noted Intel lowered its capital expenditures guidance which he said was the "right step" in order for the company to return to positive free cash flow in 2025. Muse maintained a Neutral rating and $22 price target on Intel stock.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/earnings/25/01/43400701/ups-ceo-says-amazon-is-our-largest-but-not-our-most-profitable-customer">UPS CEO Says Amazon Is &#8216;Our Largest,&#8217; But &#8216;Not Our Most Profitable Customer&#8217;&nbsp;</a>
Oppenheimer analysts noted all product segments guided down by approximately 14% for the first quarter and that Intel continues to lose market share to Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) in both its Client Computing Group and Data Center segments. 
Oppenheimer said it "remains on the sidelines as turnaround efforts take root" and maintained a Perform rating on Intel shares.&nbsp;
Stifel analysts also pointed to the company's reduced guidance and slow recovery and remain on the sidelines "until execution starts yielding results." Stifel maintained its Hold rating on Intel but lowered its price target from $25 to $21.&nbsp;
Several other analysts <a href="https://www.benzinga.com/quote/INTC/analyst-ratings">updated coverage</a> on Intel following the fourth-quarter print:&nbsp;
<ul>
<li>JPMorgan analyst Harlan Sur maintained Intel with an Underweight and lowered the price target from $26 to $23.</li>
<li>Wells Fargo analyst Aaron Rakers maintained an Equal-Weight rating but lowered the price target on Intel from $28 to $25.</li>
<li>Benchmark analyst Cody Acree reiterated Intel with a Hold rating.&nbsp;</li>
<li>Needham analyst Quinn Bolton reiterated a Hold rating.&nbsp;</li>
</ul>
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43320124/microsoft-shares-slide-after-q2-results-cloud-revenue-misses-expectations-details">Microsoft Shares Slide After Q2 Results, Cloud Revenue Misses Expectations: Details</a>&nbsp;</li>
</ul>
Photo: Shutterstock

Analyst Color

Earnings

Reiteration

Analyst Ratings

Movers

INTC

Intel Attempts Turnaround, Analysts 'Remain On The Sidelines'

8 analysts have expressed a variety of opinions on Angi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $2.77, a high estimate of $6.00, and a low estimate of $1.70. This current average represents a 16.31% decrease from the previous average price target of $3.31. 
<img src="https://www.benzinga.com/files/images/story/2025/1738360869_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Angi. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ygal Arounian</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$2.00</td>
<td>$1.70</td>
</tr>
<tr>
<td>Ygal Arounian</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.70</td>
<td>$2.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$2.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$2.50</td>
<td>$3.25</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$3.00</td>
<td>$3.25</td>
</tr>
<tr>
<td>Ygal Arounian</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$2.00</td>
<td>$3.25</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Angi. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Angi compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Angi's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Angi's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ANGI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Angi analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Angi: A Closer Look</h2>
Angi Inc connects quality home service professionals across different categories, from repairing and remodeling to cleaning and landscaping, with consumers. The Company has three operating segments namely, Ads and Leads that generate maximum revenue, Services, and International (Europe and Canada). The company operates under multiple brands that including Angi, HomeAdvisor, and Handy. The majority of the revenue is earned from the United States.
<h3>Angi: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Angi's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -15.52%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Communication Services sector.
Net Margin: Angi's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 11.85% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Angi's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.33%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Angi's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.9%, the company showcases efficient use of assets and strong financial health.
Debt Management: Angi's debt-to-equity ratio is below the industry average. With a ratio of 0.46, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANGI

The Analyst Verdict: Angi In The Eyes Of 8 Experts

Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $296.7, with a high estimate of $350.00 and a low estimate of $245.00. This upward trend is evident, with the current average reflecting a 11.33% increase from the previous average price target of $266.50.
<img src="https://www.benzinga.com/files/images/story/2025/1738360858_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Carvana. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rajat Gupta</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$277.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$280.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$330.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>David Lantz</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$275.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Jeff Lick</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$330.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Michael Montani</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$245.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Adam Jonas</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$260.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Carvana. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Carvana compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Carvana's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Carvana's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CVNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Carvana analyst ratings.</a>
<h2>Get to Know Carvana Better</h2>
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.
<h3>Unraveling the Financial Story of Carvana</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Carvana displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 31.81%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 2.33%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Carvana's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 14.95% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.17%, the company showcases effective utilization of assets.
Debt Management: Carvana's debt-to-equity ratio stands notably higher than the industry average, reaching 10.06. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CVNA

Assessing Carvana: Insights From 10 Financial Analysts

11 analysts have shared their evaluations of IAC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for IAC, revealing an average target of $68.18, a high estimate of $110.00, and a low estimate of $14.00. This current average represents a 5.54% decrease from the previous average price target of $72.18. 
<img src="https://www.benzinga.com/files/images/story/2025/1738360842_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of IAC by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ygal Arounian</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$58.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Ygal Arounian</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$56.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$54.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Tim Nollen</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>John Blackledge</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$77.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$105.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$80.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Ross Sandler</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$66.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to IAC. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of IAC compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of IAC's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/IAC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on IAC analyst ratings.</a>
<h2>Discovering IAC: A Closer Look</h2>
IAC is an internet media company with segments that include Angi (33% of total revenue), Dotdash Meredith (39%), search (14%), and emerging and other (14%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
<h3>Financial Milestones: IAC's Journey</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: IAC's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -15.53%. This indicates a decrease in the company's top-line earnings. When compared to others in the Communication Services sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -25.96%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): IAC's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -4.14%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): IAC's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -2.43%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: IAC's debt-to-equity ratio is below the industry average at 0.35, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 11 Analysts Discuss IAC Stock

In the latest quarter, 15 analysts provided ratings for Dow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $47.4, a high estimate of $60.00, and a low estimate of $38.00. A 10.92% drop is evident in the current average compared to the previous average price target of $53.21. 
<img src="https://www.benzinga.com/files/images/story/2025/1738360833_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Dow by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$38.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$43.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$44.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$46.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$53.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$44.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$41.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Eric Boyes</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>Outperform</td>
<td>$56.00</td>
<td>-</td>
</tr>
<tr>
<td>Duffy Fischer</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$48.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$46.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$62.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Dow. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Dow compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Dow's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Dow's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DOW/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Dow analyst ratings.</a>
<h2>Discovering Dow: A Closer Look</h2>
Dow Chemical is a diversified global chemicals producer, formed in 2019 as a result of the DowDuPont merger and subsequent separations. The firm is a leading producer of several chemicals, including polyethylene, ethylene oxide, and silicone rubber. Its products have numerous applications in both consumer and industrial end markets.
<h3>Financial Milestones: Dow's Journey</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Dow displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 1.39%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Materials sector.
Net Margin: Dow's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 1.94%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Dow's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.15%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Dow's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.36%, the company showcases efficient use of assets and strong financial health.
Debt Management: Dow's debt-to-equity ratio surpasses industry norms, standing at 0.98. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Dow Through The Eyes Of 15 Analysts

In the last three months, 11 analysts have published ratings on Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>), offering a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $35.18, along with a high estimate of $40.00 and a low estimate of $30.00. Marking an increase of 7.49%, the current average surpasses the previous average price target of $32.73. 
<img src="https://www.benzinga.com/files/images/story/2025/1738360824_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Confluent by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Howard Ma</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Sanjit Singh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$37.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Miller Jump</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Pinjalim Bora</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$31.00</td>
<td>$31.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Confluent. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Confluent compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Confluent's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Confluent's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CFLT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Confluent analyst ratings.</a>
<h2>Delving into Confluent's Background</h2>
Confluent Inc is a new category of data infrastructure designed to connect all the applications, systems, and data layers of a company around a real-time central nervous system. Its products include Confluent Platform; Connectors; ksqlDB and others. The company generates revenue from the sale of subscriptions and services. Geographically, it derives a majority of its revenue from the United States. The company provides solutions to Financial Services; Insurance; Retail and eCommerce; Automotive; Government and other sectors.
<h3>Understanding the Numbers: Confluent's Finances</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Confluent's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 24.99%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -29.63%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Confluent's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -8.2%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Confluent's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -2.89%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Confluent's debt-to-equity ratio surpasses industry norms, standing at 1.19. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CFLT

Assessing Confluent: Insights From 11 Financial Analysts

In the last three months, 5 analysts have published ratings on Cullen/Frost Bankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFR#NYSE">CFR</a>), offering a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $132.8, a high estimate of $145.00, and a low estimate of $113.00. Observing a 10.48% increase, the current average has risen from the previous average price target of $120.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1738360815_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Cullen/Frost Bankers among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$144.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>David Rochester</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Neutral</td>
<td>$145.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Brady Gailey</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$140.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>David Rochester</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Neutral</td>
<td>$122.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Ben Gerlinger</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Sell</td>
<td>$113.00</td>
<td>$104.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Cullen/Frost Bankers. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Cullen/Frost Bankers compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Cullen/Frost Bankers's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Cullen/Frost Bankers's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CFR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Cullen/Frost Bankers analyst ratings.</a>
<h2>Unveiling the Story Behind Cullen/Frost Bankers</h2>
Cullen/Frost is a regional us bank with around $50 billion in assets (as of 2023 year-end), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.
<h3>Unraveling the Financial Story of Cullen/Frost Bankers</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Cullen/Frost Bankers's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 5.42%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 27.65%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.81%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.29%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Cullen/Frost Bankers's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.06.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Assess Cullen/Frost Bankers: What You Need To Know

Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) has outperformed the market over the past 20 years by 1.29% on an annualized basis producing an average annual return of 9.67%. Currently, Marvell Tech has a market capitalization of $97.66 billion. 
Buying $1000 In MRVL: If an investor had bought $1000 of MRVL stock 20 years ago, it would be worth $6,519.93 today based on a price of $112.86 for MRVL at the time of writing.
<h3>Marvell Tech's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738360811_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MRVL

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today

Raymond James Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>) has outperformed the market over the past 5 years by 9.0% on an annualized basis producing an average annual return of 21.84%. Currently, Raymond James Finl has a market capitalization of $34.47 billion. 
Buying $100 In RJF: If an investor had bought $100 of RJF stock 5 years ago, it would be worth $274.82 today based on a price of $168.48 for RJF at the time of writing.
<h3>Raymond James Finl's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738359909_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Raymond James Finl Stock In The Last 5 Years

SR Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRBK#NASDAQ">SRBK</a>) reported quarterly earnings of $0.12 per share. This is a 33.33 percent decrease over earnings of $0.18 per share from the same period last year.

SRBK

SR Bancorp Q4 EPS $0.12 Down From $0.18 YoY

It took only four sessions for the U.S. stock market to recover most of the losses triggered earlier in the week after the Chinese startup DeepSeek launched a more efficient and cost-effective AI platform than OpenAI&#8216;sChatGPT, sparking a sharp <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43239042/magnificent-seven-broadcom-lose-nearly-900-billion-in-value-as-deepseek-sparks-ai-carnage-why-this-expert-is-still-bullish-on-us-tech">selloff on Wall Street.</a>
Investors began questioning the need to allocate capital to higher-cost AI-related companies, sending shares of top chipmakers and data <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43267966/deepseeks-low-cost-model-reshapes-ai-landscape-experts-predict-shift-to-application-layer">centers into a tailspin.</a>
Yet resilient quarterly earnings reports and a significantly less hawkish Federal Reserve Chair Jerome Powell compared to his stance in December gave bulls the confidence to buy the dip.
As widely expected, the Federal Reserve left interest rates <a href="https://www.benzinga.com/25/01/43316048/fed-holds-interest-rates-steady-halts-streak-of-consecutive-cuts-as-inflation-remains-elevated">unchanged at 4.25%–4.5%.</a> Surprisingly, Powell instilled greater hopes for potential rate cuts in the future, stating that monetary <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43318325/a-different-powell-emerges-fed-chair-softens-hawkish-tone-on-interest-rates-bitcoin">policy remains "meaningfully restrictive."</a>
The scars remained visible for Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), which lost about 15% in a week, with the chipmaker falling again on Friday following reports that U.S. plans to levy a 10% tariff on China.
Risk sentiment deteriorated during Friday afternoon trading in New York amid escalating tariff concerns.
President Donald Trump said again he plans to introduce 25% tariffs on imports from Mexico and Canada, though reports differed on when it would go into effect. 
On Friday, White House press secretary Karoline Leavitt said tariffs are coming Saturday.
&#8220;The President will implement 25% [tariffs] on Mexico, Canada and 10% on China,&#8221; Leavitt stated. 
Analysts warn that such a measure could cause significant economic disruptions in North America, with the U.S. automotive industry<a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43398182/trumps-25-tariffs-could-slaughter-canada-mexico-economies-hit-us-auto-industry-analysts-warn"> among the most affected.</a>
Cruise liners were among the best performers in the S&amp;P 500 for the week, with Royal Caribbean Cruise Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>), Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) and Carnival Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) all posting double-digit percentage gains following strong <a href="https://www.benzinga.com/general/travel/25/01/43312480/royal-caribbean-cruises-posts-q4-beat-a-compelling-long-term-strategy-says-analyst">earnings from Royal Caribbean.</a>
United Parcel Service Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) was one of the worst laggards, plunging about 15% — its worst week since September 2008 — after the parcel service agreed with Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) to phase out more than 50% of the e-commerce giant&#8217;s volume by <a href="https://www.benzinga.com/25/01/43389661/these-analysts-cut-their-forecasts-on-ups-following-q4-earnings">the second half of 2026.</a>
You might have missed…
<h3 class="wp-block-heading">Microsoft AI Strength</h3>
Wall Street analysts assessed Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>)'s quarterly results, weighing Azure's slowing growth against its AI-driven potential. Despite cloud challenges, analysts said Microsoft remains a compelling investment due to its strategic <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43351098/microsoft-analysts-weigh-azure-weakness-against-ai-strength-most-compelling-investment-opportunities">advancements in artificial intelligence.</a>
<h3 class="wp-block-heading">Musk Wins Back Advertisers</h3>
Amazon.com is increasing its ad spending on X, reversing previous cuts. Apple Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NYSE">AAPL</a>) is also considering resuming ads on the platform, signaling a potential recovery in advertiser confidence <a href="https://www.benzinga.com/general/social-media/25/01/43373012/elon-musk-bringing-advertisers-back-to-x-amazon-boosts-spending-apple-considers-return">under Elon Musk's leadership.</a>
<h3 class="wp-block-heading">GM Earnings Beat</h3>
General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) exceeded earnings expectations last quarter, posting strong revenue growth. Yet the company incurred over $5 billion in charges after halting funding for its Cruise robotaxi business and <a href="https://www.benzinga.com/25/01/43263700/general-motors-stock-gains-after-q4-earnings-beat-incurs-charges-from-funding-halt-of-cruise-robotaxi-business">restructuring operations in China</a>. Analysts remain optimistic about GM&#8217;s long-term <a href="https://www.benzinga.com/25/01/43315953/general-motors-turnaround-on-track-despite-ev-roadblocks-analysts-view">growth and turnaround potential.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/01/43354861/vanguards-voo-set-to-overtake-spy-as-worlds-largest-etf-after-record-january-inflows">Vanguard&#8217;s VOO Set To Overtake SPY As World&#8217;s Largest ETF After Record January Inflows</a></li>
</ul>

Government

Large Cap

Regulations

Econ #s

Federal Reserve

AAPL

AMZN

MSFT

NCLH

NVDA

Stocks Trim DeepSeek Losses, Fed Holds Steady, Trump Slaps 25% Tariffs On Canada, Mexico: This Week In The Markets

The earnings results for Territorial Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBNK#NASDAQ">TBNK</a>) for Q4 were made public on Friday, January 31, 2025 at 04:30 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Territorial Bancorp missed estimated earnings by -150.0%, reporting an EPS of $-0.2 versus an estimate of $-0.08.
Revenue was up $7.94 billion from the same period last year.
<h3>Analysis of Past Earnings</h3>
The company missed on EPS by $0.1 in the previous quarter, leading to a 2.0% increase share price change the next day.
Here's a look at Territorial Bancorp's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.05</td>
<td>-0.03</td>
<td>0.02</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.15</td>
<td>-0.09</td>
<td>-0.06</td>
<td>0.04</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>8.10M</td>
<td>9.03M</td>
<td>9.88M</td>
<td>10.25M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>8.10M</td>
<td>8.90M</td>
<td>9.35M</td>
<td>10.02M</td>
</tr>
</tbody>
</table>

 Listen to the earnings announcement yourself by <a href="">clicking here</a>. 
To track all earnings releases for Territorial Bancorp <a href="https://www.benzinga.com/quote/TBNK/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TBNK

Earnings Breakdown: Territorial Bancorp Q4

Mustang Bio (MBIO) was granted orphan designation from the FDA for a treatment of malignant glioma, according to a post to the agency's website. Pu...

Mustang Bio treatment of malignant glioma granted FDA orphan status

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Mustang Bio ( ($MBIO) ) has provided an announcement. Mustang Bio announced a significant agreement with an institutional investor for the exercise...

Mustang Bio Secures $4M through Strategic Warrant Agreement

Mustang Bio granted orphan drug designation by FDA for its malignant glioma treatment

Mustang Bio ( ($MBIO) ) just unveiled an update. Mustang Bio, Inc. faces potential delisting from Nasdaq as its stock price remains below $1.00 for...

Mustang Bio Faces Nasdaq Delisting and Leadership Changes

Mustang Bio files to sell 34.77M shares of common stock for holders

16:20 EST Mustang Bio (MBIO) files to sell common stock and warrants, no amount given Published first on TheFly – the ultimate source for real-time...

Mustang Bio files to sell common stock and warrants, no amount given

Mustang Bio files to sell common stock, warrants

19:50 EST Mustang Bio (MBIO) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking fin...

Mustang Bio trading halted, news pending

AKBA

ALLK

APVO

CNSP

CRMD

CYCC

DBVT

GNPX

IMUX

ONCT

SGMO

SYRS

Financing

Press Releases

Mustang Bio Announces Closing of $4 Million Public Offering

Health Care

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy

Dividends

Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Opinion

Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Mustang Bio Receives Positive Listing Determination from Nasdaq

Mustang Bio Announces Reverse Stock Split

FBIO

LEGN

NRIX

ONCY

TSX:ONC

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Alzamend Neuro

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Gr

Aptevo Therapeutics

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

Galecto

GRI Bio

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Moleculin Biotech

Ocean Biomedical

Organovo Holdings

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Polyrizon

Plus Therapeutics

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Sunshine Biopharma

Soligenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

T2 Biosystems

Viracta Therapeutics, Inc. - Common Stock

Viracta Therapeutics

Xenetic Biosciences

HC Wainwright & Co.

Cantor Fitzgerald

BTIG

월요일, 미국 주요 지수는 상승세를 보였다. 다우존스 산업평균지수는 0.5% 가까이 오른 38,778.10에 마감했고, S&amp;P 500 지수는 0.8% 가까이 오른 5,473.23에, 나스닥 지수는 0.95% 상승한 17,857.02에 마감했다.
이들은 하루 동안 소매 거래자와 투자자들의 주목을 받은 인기 종목들이다:
팔란티어 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>):
팔란티어의 주가는 6.15% 상승하여 25.02달러로 마감했으며, 장중 최고가는 25.06달러, 최저가는 22.84달러이다. 해당 주식의 52주 범위는 27.50달러에서 13.56달러 사이이다. 아거스 리서치(Argus Research)의 분석가는 상업 부문으로의 확장과 정부 사업의 성장을 주요 동인으로 언급하면서 매수 등급과 29달러 목표 가격으로 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39363817/whats-going-on-with-palantirs-stock" target="_blank" rel="noopener" data-google-interstitial="false">커버를 시작</a>했다.
머스탱 바이오(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>):
머스탱 바이오의 주식은 476.92% 폭등한 0.75달러에 마감했는데, 이날 장중 최고치는 0.97달러, 최저치는 0.29달러였다. 이 종목의 52주 범위는 8.17달러에서 0.13달러다. 이 회사가 MB-106의 1/2상 임상 시험의 전체 발덴스트롬 거대글로불린혈증(Waldenstroms macroglobulinemia) 코호트에서 <a href="https://www.benzinga.com/news/24/06/39361555/crude-oil-rises-1-mustang-bio-shares-spike-higher" target="_blank" rel="noopener" data-google-interstitial="false">안전성 및 효능 데이터</a>를 발표한 후 주가가 급등했다. 이는 31개월에 한 명의 환자가 완전 관해 상태를 유지하면서 90%의 전체 반응률을 보여주었다.
참고: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39344508/as-apple-nvidia-trade-near-all-time-highs-jim-cramer-tells-investors-to-cash-in-on-ai-stocks?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">애플, 엔비디아의 주가가 사상 최고치에 다가설 때, 짐 크레이머는 투자자들에게 청산을 조언</a>
드래프트킹스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>):
드래프트킹스 주식은 7.81% 상승한 41.95달러에 마감했으며, 이날 장중 고점은 42.21달러, 저점은 38.93달러였다. 이 종목의 52주 신저가는 24.16달러에 52주 신고가는 49.57달러이다. 플로리다의 온라인 스포츠 베팅과 뉴저지의 세금 낙관주의에 영향을 미치는 <a href="https://www.benzinga.com/news/24/06/39366397/whats-going-on-with-draftkings-shares-monday">미국 연방대법원의 판결</a> 이후 이 주가가 급등했다.
마이크론 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)
이날 마이크론의 주가는 4.58% 상승한 147.83달러에 마감했다. 이날 마이크론의 주식은 52주 최고가 148.75달러, 최저가 142.14달러를 기록했다. BofA 증권과 서스퀘하나(Susquehanna)의 <a href="https://www.benzinga.com/news/24/06/39357658/micron-stock-is-moving-higher-monday-whats-going-on">분석가들은</a> 회사의 3분기 재무 결과를 앞두고 긍정적인 평가를 유지하고 목표 가격을 높였다.
테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
이날 테슬라의 주식은 5.30% 상승, 187.44달러에 마감했다. 이날 이 종목의 최고가는 188.81달러, 최저가는 177.00달러였으며, 52주 범위는 299.29달러에서 138.80달러이다. 최근 주주들은 테슬라의 CEO인 일론 머스크가 <a href="https://www.benzinga.com/24/06/39365004/teslas-boardroom-dynamics-could-impact-its-stock-performance-amidst-ceo-elon-musks-record-breaking-4" target="_blank" rel="noopener" data-google-interstitial="false">4조 4,000억달러의 연봉 패키지</a>를 받게 하기로 결정했으며, 이 밖에도 회사의 주요 경영 결정을 승인했다.
이미지는 셔터스톡을 통해 제공됐습니다.
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>에 의해 생성되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>에 의해 편집되었습니다

Comments

Mustang Bio

뉴스

에 대한 최신 뉴스 Mustang Bio (NASDAQ:MBIO) 주식

화요일, 6월 18, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌